The New England Journal of Medicine has retracted a landmark 2021 trial investigating avacopan for ANCA-associated vasculitis, a rare autoimmune disease affecting blood vessels. The retraction follows identification of significant data integrity concerns in the study led by Professor David Jayne at Cambridge University. The original trial had demonstrated avacopan’s efficacy in reducing disease activity and steroid dependence, leading to regulatory approval and widespread clinical adoption across Europe and North America. However, post-publication quality assurance processes revealed problems with data integrity that prompted this unprecedented action by one of medicine’s most influential journals. The retraction raises critical questions about trial oversight mechanisms and peer review robustness in high-impact publications. Healthcare providers treating ANCA-associated vasculitis are advised to review current clinical evidence independently and consult updated treatment guidelines. Patients currently taking avacopan should not make changes to their therapy without consulting their treating physician.
Was this article helpful?
